AltoStar® Purification Kit 1.5
The AltoStar® Purification Kit 1.5 uses magnetic particle technology and is intended to be used for automated isolation and purification of nucleic acids from specified human specimens for in vitro diagnostic purposes. The product is designed for
use with the AltoStar® Automation System AM16, the AltoStar® Internal Control 1.5 and altona Diagnostics kits and reagents specified for use with the AltoStar® Purification Kit 1.5.
The AltoStar® Purification Kit 1.5 is intended for use by professional users who are trained in molecular biological techniques.
AltoStar® Purification Kit 1.5 -Delivery of two boxes
The AltoStar® Purification Kit 1.5 is a nucleic acid isolation and purification kit. It permits the simultaneous purification of RNA and DNA from multiple sample types on the AltoStar® Automation System AM16. 
AltoStar® Purification Kit 1.5 - Box 1 contains 6 different boxes (see Content of Box 1). 
AltoStar® Purification Kit 1.5 - Box 2 contains 6 trays with tubes (see Content of Box 2).
Key Features
- DNA and RNA Purification in parallel
- All sample types in one run
- Combine up to eight assays on a 96-well plate
- Analyze up to four pathogens from a single sample
- Scalable from 1-96, no minimum batch size
- Sample carriers can be unloaded at any time after sample processing
Kit Content
All reagents included in the AltoStar® Purification Kit 1.5 are ready-to-use solutions and are shipped in two separate boxes: Box 1 and Box 2. The boxes are shipped at room temperature.
Box 1 (with 6 different boxes inside) has to be stored at +15 °C to +30 °C and
Box 2 (with 6 trays inside) has to be stored at +2 °C to +8 °C upon receipt.
The AltoStar® Purification Kit 1.5 contains reagents sufficient for 1152 sample purifications with a 500 µl sample volume, or for 576 sample purifications with a 1000 µl sample volume.
AltoStar® Purification Kit 1.5 - Content of Box 1 (with 6 different boxes inside)
Box 1 AltoStar® Purification Kit 1.5: The Whole Blood Pretreatment Buffer contains surfactants and salts to stabilize and liquify whole blood samples for automated processing on the AltoStar® AM16 (8 x bottles, Box 1/6). 
Box 1 AltoStar® Purification Kit 1.5: The Lysis Buffer contains chaotropic salts (guanidine thiocyanate, Octoxynol 9) to disrupt cells or virions chemically. It stabilizes nucleic acids and protects them against nucleases in solution (6 x containers, Box 2/6). 
AltoStar® Purification Kit 1.5 (Box 1): The Wash Buffer 1 contains different salts and organic solvents (guanidine thiocyanate and ethanol) to remove proteins and other impurities (6 x containers, Box 3/6). 
AltoStar® Purification Kit 1.5 (Box 1): The Wash Buffer 2 contains organic solvents (ethanol) to remove proteins and other impurities (6 x containers, Box 4/6). 
Box 1 AltoStar® Purification Kit 1.5: The Wash Buffer 3 contains different salts in order to purify the nucleic acids (6 x containers, Box 5/6). 
Box 1 AltoStar® Purification Kit 1.5: Container Re-Sealing Foil for the AltoStar® Purification Kit 1.5 Lysis Buffer and Wash Buffer 1, 2, and 3 containers (120 units, Box 6/6).
AltoStar® Purification Kit 1.5 - Content of Box 2 (6 trays with tubes inside)
Box 2 AltoStar® Purification Kit 1.5: This box contains 6 trays. The Enhancer stabilizes and protects nucleic acids against nucleases in solution. The Magnetic Beads are coated with a thin layer of silica to bind free nucleic acids in solution. The magnetic characteristic allows the separation of beads from liquids in a magnetic field. The Elution Buffer is a low salt buffer to elute the nucleic acids from the magnetic beads for subsequent analysis. 
Box 2 AltoStar® Purification Kit 1.5: One tray comprises 4 tubes Magnetic Beads, 2 tubes Elution Buffer and 4 tubes Enhancer.
AltoStar® Purification Kit 1.5
| Order No. | PK15-16 |
| Sample purifications | 1152 (500 µl sample volume, low volume) or 576 (1000 µl sample volume, high volume) |
| Sample Types | Human EDTA and citrate whole blood Human serum Human EDTA and citrate plasma Human urine Human stool Swabs in viral transport medium Human cerebrospinal fluid (CFS) |
| Transportation | Room temperature |
| For use with | AltoStar® Automation System AM16 AltoStar® Internal Control 1.5 AltoStar® PCR kits CFX96™ Deep Well Dx System |
AltoStar® Purification Kit 1.5
| Release Date: | 03/2021 |
| Date de sortie: | 03/2021 |
| Fecha de lanzamiento: | 03/2021 |
| Data de lançamento: | 03/2021 |
| Data di rilascio: | 03/2021 |
| Release Date: | 10/2020 |
Principle of Method
The AltoStar® Purification Kit 1.5 is intended for automated isolation and purification of RNA and DNA from specified biological specimens for in vitro diagnostic purposes in conjunction with the AltoStar® AM16, the AltoStar® Internal Control 1.5, was well as with the altona Diagnostics kits and reagents, which are specified for use with the AltoStar® Purification Kit 1.5. The AltoStar® Purification Kit 1.5 is based on magnetic bead technology, utilizing silica-coated magnetic particles, which can bind and release nucleic acids under specific conditions.
The purification procedure comprises 3 automated steps on the AltoStar® AM16 (see Fig.).
1. In the first step nucleic acids are released by chemical and mechanical lysis under chaotropic high salt conditions. The conditions stabilize the nucleic acids in solution and enable their binding to the magnetic silica beads. The AltoStar® Internal Control 1.5 is automatically added by the AltoStar® AM16.
2. In the following washing steps different wash buffers are used to remove proteins and other impurities.
3. Finally the nucleic acids are released from the magnetic beads with an elution buffer and transferred to the eluate plate.
AltoStar® Purification Kit 1.5
Konformitätserklärung/Declaration of Conformity/Déclaration de conformité (DE, EN, FR)
pdf| Veröffentlichungsdatum/Release date/Date de sortie: | 06.10.2020 |
Declaración de conformidad/Dichiarazione di Conformità/Declaração de conformidade (ES, IT, PT)
pdf| Fecha de lanzamiento/Data di rilascio/Data de lançamento: | 06.10.2020 |
| Release Date: | 11/2018 |
| Date de sortie: | 11/2018 |